COLUMBUS, OH - July 20, 2012 (Investorideas.com Newswire, www.biodfensestocks.com) Biodefense News alert : Battelle has won a single-source award from the U.S. Department of Health and Human Services' National Institutes of Health for evaluation and testing services for vaccines and other biologics for infectious diseases. The work, worth as much as $102.5 million for 10 years, will be conducted at Battelle's biosafety level 3 laboratories and new toxicology research facility in West Jefferson, Ohio.
The award will support the National Institute of Allergy and Infectious Diseases (NIAID) Division of Microbiology and Infectious Diseases (DMID) in development of medical countermeasures against infectious diseases, including vaccines and biologics directed against emerging and biodefense pathogens.
"This contract is exactly the type of work we are built for at Battelle," said Barbara Kunz, President of Battelle's Health and Life Sciences Global Business. "It spans several areas of expertise and supports the government clients that we hold in high regard."
The effort provides for a diverse suite of preclinical, nonclinical and clinical testing on an as-needed basis to obtain critical data that will contribute to an eventual decision by the Food and Drug Administration about the product's safety and efficacy.
The contract will evaluate the efficacy, immunogenicity, and safety of vaccines and analyze samples from clinical trials. These services are intended to help a wide variety of investigators obtain critical data needed to acquire additional funding, gain prospective partnerships, fulfill regulatory requirements, and complete studies needed to apply for an IND and enter Phase I/II/III clinical trials.
As the world's largest independent research and development organization, Battelle provides innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.5 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus , Ohio , Battelle oversees 22,000 employees in more than 130 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security and a nuclear energy lab in the United Kingdom.
Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.
Katy Delaney (614) 424-7208
T.R. Massey (614) 424-5544
This news is published on the Investorideas.com Newswire and its syndicated partner network
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.